These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35946133)

  • 1. Effect of social disparities on 10 year survival in pediatric patients with Wilms' tumor.
    Chalfant V; Riveros C; Stec AA
    Cancer Med; 2023 Feb; 12(3):3452-3459. PubMed ID: 35946133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Surveillance, Epidemiology and End Results (SEER) program comparison of adult and pediatric Wilms' tumor.
    Ali AN; Diaz R; Shu HK; Paulino AC; Esiashvili N
    Cancer; 2012 May; 118(9):2541-51. PubMed ID: 21918969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Social Disparities on 5-Year Survival Rates in Pediatric Hematologic Malignancies.
    Chalfant V; Riveros C; Bechtel A; Bradfield SM; Stec AA
    J Pediatr Hematol Oncol; 2024 Jan; 46(1):33-38. PubMed ID: 37910818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting lymph node sampling patterns and the impact on survival of lymph node density in patients with Wilms tumor: a Surveillance, Epidemiology, and End Result (SEER) database review.
    Walker JP; Johnson JS; Eguchi MM; Saltzman AF; Cockburn M; Cost NG
    J Pediatr Urol; 2020 Feb; 16(1):81-88. PubMed ID: 31791906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metachronous bilateral Wilms' tumor: the importance of time interval to the development of a second tumor.
    Paulino AC; Thakkar B; Henderson WG
    Cancer; 1998 Jan; 82(2):415-20. PubMed ID: 9445201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, clinical features and treatment outcome of Wilms' tumor in Taiwan: a report from Taiwan Pediatric Oncology Group.
    Hung IJ; Chang WH; Yang CP; Jaing TH; Liang DC; Lin KH; Lin DT; Hsiao CC; Hsieh YL; Chen JS; Chang TT; Peng CT; Shu SG; Lin MT; Chen BW; Lin KS;
    J Formos Med Assoc; 2004 Feb; 103(2):104-11. PubMed ID: 15083240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor at the Children's Hospital of Eastern Ontario: 1990-2001.
    Pianezza ML; Rubin S; Bass J; Chou S; Pike JG; Leonard MP
    Can J Urol; 2004 Feb; 11(1):2151-6. PubMed ID: 15003157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.
    Oue T; Koshinaga T; Takimoto T; Okita H; Tanaka Y; Nozaki M; Haruta M; Kaneko Y; Fukuzawa M;
    Pediatr Surg Int; 2016 Sep; 32(9):851-5. PubMed ID: 27473009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilms' tumor: past, present and (possibly) future.
    Spreafico F; Bellani FF
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):249-58. PubMed ID: 16445377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.
    Green DM; Breslow NE; Beckwith JB; Takashima J; Kelalis P; D'Angio GJ
    J Clin Oncol; 1993 Jan; 11(1):91-5. PubMed ID: 8380295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of lymph node sampling and the impact of lymph node density in favorable histology Wilms tumor: An analysis of the national cancer database.
    Saltzman AF; Carrasco A; Amini A; Aldrink JH; Dasgupta R; Gow KW; Glick RD; Ehrlich PF; Cost NG
    J Pediatr Urol; 2018 Apr; 14(2):161.e1-161.e8. PubMed ID: 29133167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between different levels of lipid metabolism‑related enzymes and fatty acid synthase in Wilms' tumor.
    Wang X; Du G; Wu Y; Zhang Y; Guo F; Liu W; Wu R
    Int J Oncol; 2020 Feb; 56(2):568-580. PubMed ID: 31894270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
    Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
    J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized Wilms' tumor in low-middle-income countries (LMIC): how can we get better?
    Asfour HY; Khalil SA; Zakaria AS; Ashraf ES; Zekri W
    J Egypt Natl Canc Inst; 2020 Aug; 32(1):32. PubMed ID: 32794016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group.
    Pritchard-Jones K; Kelsey A; Vujanic G; Imeson J; Hutton C; Mitchell C; ;
    J Clin Oncol; 2003 Sep; 21(17):3269-75. PubMed ID: 12947062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy in Wilms' tumour.
    Thomas PR
    Ann Acad Med Singap; 1996 May; 25(3):425-8. PubMed ID: 8876911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
    Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
    Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor.
    Ortiz MV; Ahmed S; Burns M; Henssen AG; Hollmann TJ; MacArthur I; Gunasekera S; Gaewsky L; Bradwin G; Ryan J; Letai A; He Y; Naranjo A; Chi YY; LaQuaglia M; Heaton T; Cifani P; Dome JS; Gadd S; Perlman E; Mullen E; Steen H; Kentsis A
    JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.